Each year, more CMOs expand their service offerings to include specialized development capabilities, particularly contract manufacturers focused on biologic drugs. Cell line development, process, analytical and formulation development, clinical trial manufacturing and commercial manufacturing for drug substance and drug product may be obtained from a single provider with end-to-end services.
Knowing whether this is the best approach for your organization is challenging. This report dives into how the decision-making process differs among drug innovators outsourcing development activities from those outsourcing commercial manufacturing when it comes to CMO/CDMO selection criteria, use patterns, preferences and perceived leadership.
Readers will gain insight into four different outsourcing scenarios for biologic drugs enabling them to make more educated purchases of CMO services based on their unique needs. CMOs will gain a better understanding of customers’ requirements and how they change as a compound moves through the development to commercialization process.
How you can use this report
Drug Developers - Differences in CMO engagement and usage patterns based on outsourcing stage and internal capabilities and/or capacity - Key differences in CMO selection drivers based on four different outsourcing scenarios: development-stage API manufacturing, commercial API manufacturing, development-stage drug product manufacturing and commercial drug product manufacturing - Learn which CMO attributes are becoming more important to different types of outsourcing peers in order to gain advantages from their experiences
Contract Manufacturers - Ways to improve your company’s sales and marketing strategies to specifically address the needs of different customer bases, as identified in CMO selection criteria, during specific decision-making scenarios - Outsourcing propensity of the different buyers of outsourced services for both drug substance and drug product manufacturing - How CMO awareness, familiarity, leadership, proposal volume, use and preference vary between outsourcers of development-stage or commercial-scale manufacturing in order to target specific audiences with the precise information they need
Major topics - Outsourcing Philosophies and Practices - CMO Perceptions and Interactions - CMO Selection Drivers - Study Data
Our reports have been used by over 10K customers, including:
The Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading biopharma companies. This report provides...
188 pages •
By Global Industry Analysts
• Apr 2021
- Global Bone Morphogenetic Proteins Market to Reach $589.5 Million by 2027
- Amid the COVID-19 crisis, the global market for Bone Morphogenetic Proteins estimated at US$508 Million in the year 2020, is projected to reach a revised size of US$589.5 Million by 2027, growing at aCAGR of 2.1% over the period...
174 pages •
By Global Industry Analysts
• Apr 2021
- Global Biopharmaceuticals Manufacturing Consumables Testing Market to Reach $797.1 Million by 2027
- Amid the COVID-19 crisis, the global market for Biopharmaceuticals Manufacturing Consumables Testing estimated at US$390.7 Million in the year 2020, is projected to reach a revised size of US$797.1 Million...
Forecasts by Product (Consumables, Instruments, Software & Services), by Protein Type (Monoclonal Antibodies, Insulin, Vaccines, Erythropoietins, Colony-Stimulating Factors, Growth Hormones, Coagulation Factors, Interferons, Other Proteins), by Technology (Rational Protein Design, Irrational Protein Design, Hybrid Protein Design),...
Biopharmaceuticals Contract Manufacturing Market Report Overview Biopharmaceuticals Contract Manufacturing market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Biopharmaceuticals Contract Manufacturing market types and applications. It is...
The Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2021: Deal trends, players and financials report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right...
The Global Antibody Partnering Terms and Agreements 2014 to 2021 report provides comprehensive understanding and unprecedented access to the Antibody partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies...
The Global Precision Medicine Partnering Terms and Agreements 2014-2021 report provides comprehensive understanding and unprecedented access to the Precision Medicine partnering deals and agreements entered into by the worlds leading healthcare companies. This report provides details of the latest Precision Medicine...
The Global Stem Cell Partnering Terms and Agreements 2010-2021 report provides comprehensive understanding and unprecedented access to the stem cell partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in stem cell partnering Deal terms analysis Partnering agreement structure Partnering...
175 pages •
By The Business Research Company
• Apr 2021
Major players in the oral biologics and biosimilar market are Novartis, Rani Therapeutics, Eli Lilly and Co., AstraZeneca plc, Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, BiosanaPharma, Entera Bio Ltd. and Allergan plc. The global oral biologics & biosimilar drugs market is expected to grow from $3.53 billion in 2020 to...
Chronic Disease Prevalence
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.